• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
NEU 2.33% $18.85

NEUREN PHARMACEUTICALS LIMITED

Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing... Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing therapies for neurodevelopmental disorders. The Company is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The Company has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of trofinetide.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Latest Threads

Tag Subject Date Created with Sketch. Comments Created with Sketch. Views Created with Sketch.
NEU 18:11 75 23K
18:11 Last post  hottod Comments Created with Sketch.  75  Views Created with Sketch.  23K 
NEU 17:00 15 4.6K
17:00 Last post  kens Comments Created with Sketch.  15  Views Created with Sketch.  4.6K 
NEU
Share Price
12:48 9.9K 4.4M
12:48 Last post  htae39 Comments Created with Sketch.  9.9K  Views Created with Sketch.  4.4M 
NEU 11:47 92 40K
11:47 Last post  Richo24 Comments Created with Sketch.  92  Views Created with Sketch.  40K 
NEU 23/04/24 8 4.0K
23/04/24 Last post  ashgood123 Comments Created with Sketch.  8  Views Created with Sketch.  4.0K 
NEU
TROFINETIDE PRIORITY REVIEW IN CANADA
23/04/24 3 2.1K
23/04/24 Last post  FATNANA1 Comments Created with Sketch.  3  Views Created with Sketch.  2.1K 
NEU 23/04/24 0 403
23/04/24 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  403 
NEU 19/04/24 48 27K
19/04/24 Last post  frogga Comments Created with Sketch.  48  Views Created with Sketch.  27K 

See All Discussions arrow Created with Sketch.

Timeline

Q1 2024 quarterly activity and cash flow report
24 Apr 10:05
 
Trofinetide accepted for Priority Review by Health Canada
23 Apr 09:43
 
Appendix 4G
23 Apr 09:21
 
2023 Annual Report to shareholders
23 Apr 09:16
 
Application for quotation of securities - NEU
08 Apr 16:26
 
Application for quotation of securities - NEU
12 Mar 14:24
 
View More arrow Created with Sketch.
(20min delay)
Last
$18.85
Change
-0.450(2.33%)
Mkt cap ! $2.407B
Open High Low Value Volume
$19.30 $19.52 $18.82 $5.080M 266.2K

Buyers (Bids)

No. Vol. Price($)
2 2337 $18.85
 

Sellers (Offers)

Price($) Vol. No.
$18.91 265 1
View Market Depth
Last trade - 16.10pm 24/04/2024 (20 minute delay) ?
Last
$18.90
  Change
-0.450 ( 2.04 %)
Open High Low Volume
$19.33 $19.52 $18.82 19664
Last updated 15.59pm 24/04/2024 ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.